Literature DB >> 2568441

Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man.

S Björkman1, L O Elisson, J Gabrielsson.   

Abstract

Quinacrine was given by intrapleural instillation or intravenous infusion to 10 rabbits. The uptake of quinacrine from the pleural space was rapid and complete. The mean absorption half-life was approximately 7 min and the mean bioavailability was slightly in excess of 100%. Similar absorption characteristics generally applied in man, in a pilot study on four patients. In three of them, peak quinacrine plasma concentrations were reached that were far above the normal therapeutic range. Known systemic side-effects of quinacrine comprise CNS stimulation, toxic psychosis and convulsions. In view of the high bioavailability and the large doses used for pleural sclerosing (pleurodesis) in patients, neurological disease and psychiatric disturbances that predispose to CNS toxicity should be considered as contraindications to intrapleural quinacrine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568441     DOI: 10.1111/j.2042-7158.1989.tb06421.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  10 in total

1.  Quinacrine induced mood disturbance--the unmasking of bipolar affective disorder.

Authors:  John Lally; Fintan Byrne; Elizabeth Walsh
Journal:  BMJ Case Rep       Date:  2012-06-21

Review 2.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 3.  Interventions for the management of malignant pleural effusions: a network meta-analysis.

Authors:  Amelia O Clive; Hayley E Jones; Rahul Bhatnagar; Nancy J Preston; Nick Maskell
Journal:  Cochrane Database Syst Rev       Date:  2016-05-08

4.  Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

Authors:  Reza Ehsanian; Carter Van Waes; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2011-05-15       Impact factor: 5.712

5.  Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters.

Authors:  Lucy Martinez-Guerrero; Xiaohong Zhang; Kimberley M Zorn; Sean Ekins; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2021-07-12       Impact factor: 4.402

6.  Interventions for the management of malignant pleural effusions: a network meta-analysis.

Authors:  Alexandra Dipper; Hayley E Jones; Rahul Bhatnagar; Nancy J Preston; Nick Maskell; Amelia O Clive
Journal:  Cochrane Database Syst Rev       Date:  2020-04-21

7.  Pharmacokinetics of quinacrine in the treatment of prion disease.

Authors:  Lotus Yung; Yong Huang; Pierre Lessard; Giuseppe Legname; Emil T Lin; Michael Baldwin; Stanley B Prusiner; Chongsuk Ryou; B Joseph Guglielmo
Journal:  BMC Infect Dis       Date:  2004-11-29       Impact factor: 3.090

8.  Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms.

Authors:  Ana C Puhl; Ethan James Fritch; Thomas R Lane; Longping V Tse; Boyd L Yount; Carol Queiroz Sacramento; Tatyana Almeida Tavella; Fabio Trindade Maranhão Costa; Stuart Weston; James Logue; Matthew Frieman; Lakshmanane Premkumar; Kenneth H Pearce; Brett L Hurst; Carolina Horta Andrade; James A Levi; Nicole J Johnson; Samantha C Kisthardt; Frank Scholle; Thiago Moreno L Souza; Nathaniel John Moorman; Ralph S Baric; Peter Madrid; Sean Ekins
Journal:  bioRxiv       Date:  2020-12-02

Review 9.  Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi.

Authors:  Lucie Peyclit; Hanane Yousfi; Jean-Marc Rolain; Fadi Bittar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-20

10.  Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma.

Authors:  Jennifer Bryant; Nikolaos Batis; Anna Clara Franke; Gabriella Clancey; Margaret Hartley; Gordon Ryan; Jill Brooks; Andrew D Southam; Nicholas Barnes; Joanna Parish; Sally Roberts; Farhat Khanim; Rachel Spruce; Hisham Mehanna
Journal:  Oncotarget       Date:  2019-08-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.